# Beijing Lvzhu Biological Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-lvzhu-biological-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.luzhubiotech.com
- Total disclosed funding: $73M
- Latest round: Series C (Jun 28, 2022)
- Investors on record: 11

## About

Based in Beijing, China and established in 2001, Beijing Lvzhu Biological Technology Co.,Ltd. is a biological technology company that focuses on the development of human vaccines and therapeutic monoclonal antibodies. In 2002, the company launched a quantitative detection kit for meningococcal polysaccharide antibodies of groups A and C to the market. In 2010, the company started the research and development of antibody drugs. In 2018, the company established a subsidiary Lvzhu Biopharmaceutical in Zhuhai. In April 2023, it raised HKD 340.79 million in an IPO and listed on the Hongkong stock exchange.

The company engages in the development of human vaccines and therapeutic monoclonal antibodies. Its main products include recombinant vaccines, double antibody injections and enzyme-linked kits, etc. The products of the company include Group A Meningococcal Polysaccharide IgG Antibody Kit , Group C Meningococcal Polysaccharide IgG Antibody Kit , Group Y Meningococcal Polysaccharide IgG Antibody Kit, etc. K193 antibody injection is a bispecific antibody targeting human CD19 and CD3e, used to treat B-cell lymphoma and leukemia. 

The company will accelerate the clinical trial of the company's own innovative recombinant herpes zoster vaccine, LZ901, in China and the United States, and clinical phase I/II studies of a bifunctional antibody CD19-CD3 for the treatment of relapsed/refractory B-cell leukemia (ALL) and for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).

## Funding rounds

- Series C, Jun 28, 2022 — E-Town International Industrial Investment, CNCB (Hong Kong) Investment, Ruijiu Venture Capital
- Series B, Jan 29, 2022, $19M — Casstar Capital, MF Capital
- Series B, Aug 30, 2021, $54M — CCB International Asset Management, Tigermed, Livzon Pharmaceutical Group Inc.
- Series A, Jan 1, 2019 — Beijing Science Sun Pharmaceutical Co., Ltd, KiRin Capital, E-town Sun Fund

## Investors

- Beijing Science Sun Pharmaceutical Co., Ltd — Series A
- KiRin Capital (https://capitalatlas.ai/funds/kirin-capital) — Series A
- E-town Sun Fund (https://capitalatlas.ai/funds/e-town-sun-fund) — Series A
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series B
- Livzon Pharmaceutical Group Inc. — Series B
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Series B
- MF Capital (https://capitalatlas.ai/funds/mf-capital) — Series B
- E-Town International Industrial Investment (https://capitalatlas.ai/funds/e-town-international-industrial-investment) — Series C
- CNCB (Hong Kong) Investment (https://capitalatlas.ai/funds/cncb-hong-kong-investment) — Series C
- Ruijiu Venture Capital — Series C